- Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B
-
Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Choi CS, Kim HC
- KMID: 1713959
- J Korean Med Sci.
- 2010 May;25(5):738-745.
- doi: 10.3346/jkms.2010.25.5.738
The authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naive patients with HBeAg positive chronic hepatitis B. In this retrospective study, a... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Efficacy of Clevudine, Entecavir and Lamivudine in Treatment-naive Patients with HBeAg-Positive Chronic Hepatitis B
-
Bae SH, Baek YH, Lee SW, Han SY
- KMID: 1775852
- Korean J Gastroenterol.
- 2010 Dec;56(6):365-372.
- doi: 10.4166/kjg.2010.56.6.365
BACKGROUND/AIMS: Clevudine is a potent antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. This study compared the efficacy of clevudine (C), entecavir (E) and lamivudine (L)... -
- CITED
-
- Close
- SHARE
-
- Close
